NCT00257361

Brief Summary

We propose to undertake an initial study of DCS to determine whether it has any short-term clinical benefits when added to standard ERP therapy in adults with OCD.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2005

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 18, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 22, 2005

Completed
Last Updated

September 30, 2013

Status Verified

August 1, 2011

First QC Date

November 18, 2005

Last Update Submit

September 27, 2013

Conditions

Obsessive Compulsive Disorder

Outcome Measures

Primary Outcomes (1)

  • YBOCS

Secondary Outcomes (1)

  • Response rate

Interventions

D-CycloserineDRUG

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • a principal diagnosis of OCD assigned at pre-treatment, derived from the ADIS-IV, with a clinical severity rating of 4 or above;
  • years of age; and,
  • an IQ of ³ 80.

You may not qualify if:

  • positive diagnosis of schizophrenia, other psychotic disorder, pervasive developmental disorder, organic brain syndrome, or mental retardation;
  • do not speak English;
  • are unwilling to attend twice weekly sessions; or,
  • is pregnant, breast feeding a child, or attempting to become pregnant (see below rationale)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Interventions

Cycloserine

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Intervention Hierarchy (Ancestors)

IsoxazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsOxazolidinonesOxazolesSerineAmino Acids, NeutralAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Eric Storch, Ph.D.

    University of Florida

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2005

First Posted

November 22, 2005

Study Start

July 1, 2005

Last Updated

September 30, 2013

Record last verified: 2011-08